EP0594749A1 - Compositions pf4 et procedes d'utilisation desdites compositions - Google Patents

Compositions pf4 et procedes d'utilisation desdites compositions

Info

Publication number
EP0594749A1
EP0594749A1 EP92915801A EP92915801A EP0594749A1 EP 0594749 A1 EP0594749 A1 EP 0594749A1 EP 92915801 A EP92915801 A EP 92915801A EP 92915801 A EP92915801 A EP 92915801A EP 0594749 A1 EP0594749 A1 EP 0594749A1
Authority
EP
European Patent Office
Prior art keywords
entity
glu
polypeptide conjugate
leu
angiostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92915801A
Other languages
German (de)
English (en)
Inventor
Theodore E. Maione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Publication of EP0594749A1 publication Critical patent/EP0594749A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilisation de facteur plaquettaire 4 (PF4) et de PF4 recombinant (rPF4) ainsi que d'analogues modifiés (mutants) de PF4 et de fragments peptidiques de PF4 en vue d'inhiber l'angiogenèse. On montre que le PF4 modifié, des analogues et certains fragments ont une utilité pour traiter les maladies angiogéniques et pour inhiber la prolifération des cellules endothéliales. La présente invention concerne également des modifications de PF4 qui prolongent la demi-vie et facilitent le ciblage de l'activité biologique du PF4 sur des sites spécifiques.
EP92915801A 1991-07-15 1992-07-15 Compositions pf4 et procedes d'utilisation desdites compositions Ceased EP0594749A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73122291A 1991-07-15 1991-07-15
US731222 1991-07-15
PCT/US1992/005903 WO1993002192A1 (fr) 1991-07-15 1992-07-15 Compositions pf4 et procedes d'utilisation desdites compositions

Publications (1)

Publication Number Publication Date
EP0594749A1 true EP0594749A1 (fr) 1994-05-04

Family

ID=24938612

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92915801A Ceased EP0594749A1 (fr) 1991-07-15 1992-07-15 Compositions pf4 et procedes d'utilisation desdites compositions

Country Status (4)

Country Link
EP (1) EP0594749A1 (fr)
JP (1) JPH06509116A (fr)
CA (1) CA2113206A1 (fr)
WO (1) WO1993002192A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
JPH06506702A (ja) * 1992-01-16 1994-07-28 レプリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
WO1995012414A1 (fr) * 1993-11-05 1995-05-11 Repligen Corporation Nouvelles compositions a base de pf4 modifie et procedes d'utilisation
US5789539A (en) * 1994-10-26 1998-08-04 Repligen Corporation Chemokine-like proteins and methods of use
DE19505960A1 (de) 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US5719167A (en) * 1995-08-07 1998-02-17 Alcon Laboratories, Inc. Angiostatic compounds
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
NO20034351D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av endometrose
EA201400993A1 (ru) 2012-03-08 2015-05-29 Галозим, Инк. Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
WO2019118937A1 (fr) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps
JPH01503513A (ja) * 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9302192A1 *

Also Published As

Publication number Publication date
JPH06509116A (ja) 1994-10-13
CA2113206A1 (fr) 1993-02-04
WO1993002192A1 (fr) 1993-02-04

Similar Documents

Publication Publication Date Title
US5112946A (en) Modified pf4 compositions and methods of use
US5284827A (en) Systemic treatment of metastatic cancer with platelet factor 4
US6051549A (en) Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof
JP4295831B2 (ja) 改変された腫瘍壊死因子
AU770381B2 (en) Homing pro-apoptotic conjugates and methods of using same
EP0594749A1 (fr) Compositions pf4 et procedes d'utilisation desdites compositions
US20100285103A1 (en) Medicament for treatment of tumors and the use thereof
NZ221923A (en) Detoxified pseudomonas exotoxin, recombinant production, conjugates and compositions
JP2002530273A (ja) 脈管形成および腫瘍増殖の新規インヒビター
EP0541716A1 (fr) Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
US20010046498A1 (en) Chimeric prostate-homing peptides with pro-apoptotic activity
JP4067117B2 (ja) 選択性スロンビン抑制剤としてのブラジキニン同族体
CA2045692A1 (fr) Procedes de production des inhibiteurs polypeptiques de l'activation plaquettaire et methodes, combinaisons et compositions faisant appel a ces procedes
US5800820A (en) Methods and compositions for treatment of angiogenic diseases
EP0800533A1 (fr) Peptides cd14 anti-inflammatoires
US20030180295A1 (en) Angiocidin: a Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
US20040009914A1 (en) Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
AU2003225860B2 (en) EGFR ligands and methods of use
US8470772B2 (en) Leptin agonist and methods of use
NZ537634A (en) The use of an immunogenic conjugate comprising at least one VEGF peptide moiety coupled to a carrier for use in combating tumours
US5951981A (en) Thrombolytic agents with antithrombotic activity
CA2106368A1 (fr) Methodes et compositions pour le traitement de la maladie angiogenique
WO1995012414A1 (fr) Nouvelles compositions a base de pf4 modifie et procedes d'utilisation
WO1994025057A1 (fr) Antagonistes de la liaison du kgf derives du recepteur de kgf
WO1998016548A1 (fr) Peptides recepteurs de thrombine et utilisations correspondantes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17P Request for examination filed

Effective date: 19940208

17Q First examination report despatched

Effective date: 19950707

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RHK1 Main classification (correction)

Ipc: C12N 15/19

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970606